Workflow
Eterna Therapeutics (ERNA) - 2024 Q3 - Quarterly Report
ERNAEterna Therapeutics (ERNA)2024-11-12 22:16

Financing Activities - The company closed a private placement on October 29, 2024, selling 1,401,994 shares and pre-funded warrants for approximately 1.1millioningrossproceeds[147].−Thecompanyissued38,302,029sharesinexchangeforapproximately1.1 million in gross proceeds[147]. - The company issued 38,302,029 shares in exchange for approximately 8.7 million in convertible notes and warrants, with an exercise price of 1.43pershare[148].−Thecompanyconvertedapproximately1.43 per share[148]. - The company converted approximately 3.0 million of bridge notes into 6,244,237 shares at a conversion price of 0.50[152].−ThecompanyregainedcompliancewithNasdaqlistingrulesafterissuingover45.9millionshares,resultinginstockholders′equityexceeding0.50[152]. - The company regained compliance with Nasdaq listing rules after issuing over 45.9 million shares, resulting in stockholders' equity exceeding 2.5 million[163]. Revenue and Income - Revenue for the three months ended September 30, 2024, was 487million,asignificantincreaseof487 million, a significant increase of 436 million compared to 51millionforthesameperiodin2023[172].−GrossincomeforthethreemonthsendedSeptember30,2024,was51 million for the same period in 2023[172]. - Gross income for the three months ended September 30, 2024, was 547 million, compared to a loss of 69millioninthesameperiodin2023,reflectingachangeof69 million in the same period in 2023, reflecting a change of 616 million[172]. - The company recognized approximately 0.5millioninpreviouslydeferredrevenuerelatedtotheLineageAgreementforthethreeandninemonthsendedSeptember30,2024[165].Expenses−Researchanddevelopmentexpensesincludecostsforcompany−sponsoredactivitiesandsupportforinvestigator−sponsoredresearch,withmajorcomponentsbeingsalaries,supplies,andpreclinicalstudycosts[167][168].−Researchanddevelopmentexpensesdecreasedbyapproximately0.5 million in previously deferred revenue related to the Lineage Agreement for the three and nine months ended September 30, 2024[165]. Expenses - Research and development expenses include costs for company-sponsored activities and support for investigator-sponsored research, with major components being salaries, supplies, and preclinical study costs[167][168]. - Research and development expenses decreased by approximately 0.4 million for the three months ended September 30, 2024, totaling 1,001million,downfrom1,001 million, down from 1,387 million in the same period in 2023[175]. - General and administrative expenses for the three months ended September 30, 2024, were 3,381million,adecreaseof3,381 million, a decrease of 668 million compared to 4,049millionforthesameperiodin2023[176].−TotalresearchanddevelopmentexpensesfortheninemonthsendedSeptember30,2024,were4,049 million for the same period in 2023[176]. - Total research and development expenses for the nine months ended September 30, 2024, were 3,446 million, down from 4,560millioninthesameperiodin2023,adecreaseof4,560 million in the same period in 2023, a decrease of 1.1 million[175]. - The total operating expenses for the three months ended September 30, 2024, were 2,806million,adecreaseof2,806 million, a decrease of 2,630 million compared to 5,436millionforthesameperiodin2023[172].NetLossandFinancialPosition−ThenetlossforthethreemonthsendedSeptember30,2024,was5,436 million for the same period in 2023[172]. Net Loss and Financial Position - The net loss for the three months ended September 30, 2024, was 26.6 million, compared to a net loss of 5.6millionforthesameperiodin2023,reflectinganincreaseinlossof5.6 million for the same period in 2023, reflecting an increase in loss of 21 million[172]. - For the nine months ended September 30, 2024, the company incurred a net loss of approximately 38.8million,comparedtoanetlossof38.8 million, compared to a net loss of 15.7 million for the same period in 2023, indicating a significant increase in losses[190]. - As of September 30, 2024, the company had cash of approximately 4.3millionandanaccumulateddeficitofapproximately4.3 million and an accumulated deficit of approximately 225.8 million[190]. - The company anticipates that it will not have sufficient capital to fund operations for the next 12 months, raising concerns about its ability to continue as a going concern[193]. Other Financial Metrics - A loss on extinguishment of debt was recorded at 22.4millionforthethreeandninemonthsendedSeptember30,2024,withnosimilartransactionintheprioryear[181].−Thecompanyrecognizedanincreaseininterestexpenseofapproximately22.4 million for the three and nine months ended September 30, 2024, with no similar transaction in the prior year[181]. - The company recognized an increase in interest expense of approximately 3.2 million for the nine months ended September 30, 2024, primarily due to convertible note financings[187]. - The net cash used in operating activities decreased by approximately 3.5millionfortheninemonthsendedSeptember30,2024,comparedtothesameperiodin2023[199].−Thecompanyrecognizedacreditof3.5 million for the nine months ended September 30, 2024, compared to the same period in 2023[199]. - The company recognized a credit of 0.1 million for the change in the fair value of contingent consideration liability for both the nine months ended September 30, 2023, and 2024[185]. Strategic Initiatives - The company plans to complete IND enabling studies and submission for its lead product ERNA-101 by 2026, focusing on triple negative breast cancer and platinum-resistant ovarian cancer[146]. - The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets to expand developmental opportunities[146]. - The company entered into an Exclusive License and Collaboration Agreement with Factor Bioscience, committing to pay 0.2millionpermonthforthefirsttwelvemonths[154][156].LegalandCompliance−Nochangesininternalcontroloverfinancialreportingduringthemostrecentfiscalquarterthatmateriallyaffectedinternalcontrols[211].−Companyisnotpartytoanymateriallegalproceedings,exceptthosedescribedinthefinancialstatements[212].LeaseandProperty−Thecompanyrecognizedagainonleaseterminationofapproximately0.2 million per month for the first twelve months[154][156]. Legal and Compliance - No changes in internal control over financial reporting during the most recent fiscal quarter that materially affected internal controls[211]. - Company is not party to any material legal proceedings, except those described in the financial statements[212]. Lease and Property - The company recognized a gain on lease termination of approximately 1.6 million and expects to save about 72millioninfuturerentalpaymentsduetotheterminationofasublease[161].−Thecompanyusedapproximately72 million in future rental payments due to the termination of a sublease[161]. - The company used approximately 0.3 million for property and equipment purchases during the nine months ended September 30, 2024, with no investing activities in the same period of 2023[200].